Pediatric AKI/CRRT 2012 Conference: Novel therapies and studies in AKI
Novel therapies mentioned at the conference for acute kidney injury (AKI) in future
- p53 si RNA
- Alpha MSH
- Mesenchymal stem cells
Translational Research Investigating Biomarkers and Endpoints for Acute Kidney Injury (TRIBE-AKI) Consortium.
- All are referred to follow this consortium for studies which are published in last 2 years. The cohort of children prospectively enrolled from 3 pediatric sites: Cincinnati Children’s Hospital Medical Center, Montreal Children’s Hospital, and Yale New-Haven Children’s Hospital as part of the consortium investigating new biomarkers in AKI is known as the Translational Research Investigating Biomarker Endpoints in Acute Kidney Injury (TRIBE-AKI).
Look out for the ASSESS-AKI Study Results
- The Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) Study was established to examine how a hospitalized episode of AKI independently affects the risk of chronic kidney disease development and progression, cardiovascular events, death, and other important patient-centered outcomes. This prospective study will enroll a cohort of 1100 adult participants with a broad range of AKI and matched hospitalized participants without AKI at three Clinical Research Centers, as well as 100 children undergoing cardiac surgery at three Clinical Research Centers.
Sidharth Kumar Sethi, MD
eAJKD Advisory Board member
Check out all of eAJKD’s coverage of the AKI in Children / PCRRT 2012 Conference here.
Dear all, see also the paper:
Nephrol Dial Transplant (2010) 25: 3167–3169
Advance Access publication 13 August 2010
Urinary biomarkers—silver bullets to faster drug development and
Michael Haase and Peter R. Mertens